Why the study?
It was unclear whether clonal hematopoiesis of indeterminate potential affects the risk of immune checkpoint inhibitor myocarditis in patients with cancer treated with immunotherapy.
Does the presence of CHIP variants increase the risk of ICI myocarditis in patients with solid tumors receiving immunotherapy?
Does the presence of CHIP variants increase the risk of ICI myocarditis in patients with solid tumors receiving immunotherapy?
CHIP independently increases the risk of ICI myocarditis in cancer patients, highlighting its potential utility for pre-treatment risk stratification and cardiac monitoring.
No takes yet. Share an insight, caveat, or question.
CHIP screening may aid ICI myocarditis risk stratification; leaves open whether targeting CHIP improves outcomes.
Chehayeb et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: